ABRAXANE® Demonstrates Significant Improvement in Progression-Free Survival Compared to Standard Chemotherapy in Advanced Melanoma Patients Read more here: http://www.sacbee.com/2012/10/25/4937522/abraxane-demonstrates-significant.html#storylink=cpy

MELBOURNE, Australia, Oct. 25, 2012 — /PRNewswire/ — Specialised Therapeutics Australia Pty Ltd today announced that abstracts for the upcoming Society for Melanoma Research meeting have been published online in the organization’s official journal at http://onlinelibrary.wiley.com/doi/10.1111/pcmr.12023/abstract.

The publication includes an abstract reviewing results from a phase III metastatic melanoma study with ABRAXANE^® (nanoparticle albumin-bound paclitaxel).

In the randomised, open-label, international study (CA033), ABRAXANE showed a statistically significant improvement in progression-free survival (PFS) in chemotherapy-naïve patients with metastatic melanoma compared to patients receiving dacarbazine chemotherapy (4.8 vs. 2.5 months, respectively (HR:0.792; 95.1% CI: 0.631, 0.992; P=0.044).
Read more here: http://www.sacbee.com/2012/10/25/4937522/abraxane-demonstrates-significant.html#storylink=cpy